# Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156

> **NCT05220072** · PHASE1 · COMPLETED · sponsor: **Bial R&D Investments, S.A.** · enrollment: 6 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Carbon-14 BIA 28-6156

## Key facts

- **NCT ID:** NCT05220072
- **Lead sponsor:** Bial R&D Investments, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-28
- **Primary completion:** 2021-10-16
- **Final completion:** 2021-10-16
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220072, "Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05220072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*